Sugammadex from the perspective of evidence-based medicine
Authors:
Adamus Milan 1; Herold Ivan 2
Authors‘ workplace:
Klinika anesteziologie, resuscitace a intenzivní medicíny
Fakultní nemocnice a Lékařská fakulta Univerzity Palackého v Olomouci
1; Anesteziologicko-resuscitační oddělení, Oblastní nemocnice Mladá Boleslav, a. s.
2
Published in:
Anest. intenziv. Med., 23, 2012, č. 5, s. 237-241
Category:
Anesthesiology - Review Article
Overview
Sugammadex is a novel drug for reversal of rocuronium or vecuronium-induced neuromuscular blockade. Compared to neostigmine, its mechanism of action (encapsulation) is not influenced by cholinesterase activity. In this article, the authors summarize the current indications of sugammadex, its advantages over neostigmine and its value in specific situations during anaesthesia.
Keywords:
neuromuscular blockade – rocuronium – encapsulation – sugammadex
Sources
1. Adamus, M. Svalová relaxace v anesteziologii – nová koncepce antagonizování nervosvalového bloku. Lékařské listy, 2010, 59, 21, s. 14–15.
2. Fink, H., Blobner, M., Jeevendra Marty, J. A. Neuromuscular blocking agents and reversal drugs. In Evers, A. S., Maze, M. (editors) Anesthetic Pharmacology. Physiological Principles and Clinical Practice: A Companion to Miller’s Anesthesia. 1. vydání. Philadelphia, Pennsylvania: Elsevier, 2004, p. 586.
3. Herold, I. Svalová relaxancia v anesteziologii a intenzivní péči. Praha: Maxdorf, 2004, 268 s.
4. Bom, A., Bradley, M., Cameron, K., Clark, J. K., Van Egmond, J., Feilden, H., MacLean, E. J., Muir, A. W., Palin, R., Rees, D. C., Zhang, M. Q. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew. Chem. Int. Ed. Engl., 2002, 41, 2, p. 266–270.
5. Eleveld, D. J., Kuizenga, K., Proost, J. K., Wierda, J. M. A temporary decrease in twitch response during reversal or rocuronium-induced muscle relaxation with small dose of sugammadex. Anesth. Analg., 2007, 104, 3, p. 582–584.
6. Fuchs-Buder, T. Less is not always more: sugammadex and the risk of underdosing. Eur. J. Anaesthesiol., 2010, 27, 10, p. 849–854.
7. Le Corre, F., Nejmeddine, S., Fatahine, C., Tayar, C., Marty, J., Plaud, B. Recurarization after sugammadex reversal in an obese patient. Can. J. Anaesth., 2011, 58, 10, p. 944–947.
8. Meyhoff, C. S., Lund, J., Jenstrup, M. T., Claudius, C., Sørensen, A. M., Viby-Mogensen, J., Rasmussen, L. S. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? Anesth. Analg., 2009, 109, 3, p. 787–792.
9. Van Lancker, P., Dillemans, B., Bogaert, T., Mulier, J. P., De Kock, M., Haspeslagh, M. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. Anaesthesia, 2011, 66, 8, p. 721–725.
10. Llauradó, S., Sabaté, A., Ferreres, E., Camprubí, I., Cabrera, A. Sugammadex ideal body weight dose adjusted by level of neuromuscular blockade in laparoscopic bariatric surgery. Anesthesiology, 2012, 117, 1, p. 93–98.
11. Lee, C., Jahr, J. S., Candiotti, K. A., Warriner, B., Zornow, M. H., Naguib, M. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology, 2009, 110, 5, p. 1020–1025.
12. Bisschops, M. M., Holleman, C., Huitink, J. M. Can sugammadex save a patient in a simulated ‘cannot intubate, cannot ventilate’ situation? Anaesthesia, 2010, 65, 9, p. 936–941.
13. Naguib, M., Kopman, A. F., Ensor, J. E. Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis. Br. J. Anaesth., 2007, 98, 3, p. 302–316.
14. Plaud, B., Debaene, B., Donati, F., Marty, J. Residual paralysis after emergence from anesthesia. Anesthesiology, 2010, 112, 4, p. 1013–1022.
15. Berg, H., Roed, J., Viby-Mogensen, J., Mortensen, C. R., Engbaek, J., Skovgaard, L. T., Kristel, J. J. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol. Scand., 1997, 41, 9, p. 1095–1103.
16. Murphy, G. S., Brull, S. J. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth. Analg., 2010, 111, 1, p. 120–128.
17. Murphy, G. S., Szokol, J. W., Marymont, J. H., Greenberg, S. B., Avram, M. J., Vender, J. S. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth. Analg., 2008, 107, 1, p. 130–137.
18. Murphy, G. S., Szokol, J. W., Avram, M. J., Greenberg, S. B., Marymont, J. H., Vender, J. S., Gray, J., Landry, E., Gupta, D. K. Intraoperative acceleromyography monitoring reduces symptoms of muscle weakness and improves quality of recovery in the early postoperative period. Anesthesiology, 2011, 115, 5, p. 946–954.
19. Donati, F. Neuromuscular monitoring: what evidence do we need to be convinced? Anesth. Analg., 2010, 111, 1, p. 6–8.
20. Miller, R. D., Ward, T. A. Monitoring and pharmacologic reversal of a nondepolarizing neuromuscular blockade should be routine. Anesth. Analg., 2010, 111, 1, p. 3–5.
21. Adamus, M., Herold, I., Cvachovec, K., Ševčík, P., Černý, V. Svalová relaxace během celkové anestezie v České republice 2010 – jednodenní prospektivní observační dotazníková studie. Anest. intenziv. Med., 2011, 22, 2, s. 82–89.
22. Naguib, M., Kopman, A. F., Lien, C.A., Hunter, J. M., Lopez, A., Brull, S. J. A survey of current management of neuromuscular block in the United States and Europe. Anesth. Analg., 2010, 111, 1, p. 110–119.
23. Debaene, B., Plaud, B., Dilly, M. P., Donati, F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology, 2003, 98, 5, p. 1042–1048.
24. Cammu, G., De Witte, J., De Veylder, J., Byttebier, G., Vandeput, D., Foubert, L., Vandenbroucke, G., Deloof, T. Postoperative residual paralysis in outpatients versus inpatients. Anesth. Analg., 2006, 102, 2, p. 426–429.
25. Menéndez-Ozcoidi, L., Ortiz-Gómez, J. R., Olaguibel-Ribero, J..M., Salvador-Bravo, M. J. Allergy to low dose sugammadex. Anaesthesia, 2011, 66, 3, p. 217–219.
26. Baldo, B. A., McDonnell, N. J, Pham, N. H. The cyclodextrin sugammadex and anaphylaxis to rocuronium: is rocuronium still potentially allergenic in the inclusion complex form? Mini Rev. Med. Chem., 2012, 12, 8, p. 701–712.
27. Kawano, T., Tamura, T., Hamaguchi, M., Yatabe, T., Yamashita, K., Yokoyama, M. Successful management of rocuronium-induced anaphylactic reactions with sugammadex: a case report. J. Clin. Anesth., 2012, 24, 1, p. 62–64.
28. Clarke, R. C., Sadleir, P. H., Platt, P. R. The role of sugammadex in the development and modification of an allergic response to rocuronium: evidence from a cutaneous model. Anaesthesia, 2012, 67, 3, p. 266–273.
29. Unterbuchner, C., Fink, H., Blobner, M. The use of sugammadex in a patient with myasthenia gravis. Anaesthesia, 2010, 65, 3, p. 302–305.
30. Blichfeldt-Lauridsen, L., Hansen, B. D. Anesthesia and myasthenia gravis. Acta Anaesthesiol. Scand., 2012, 56, 1, p. 17–22.
31. Alston, T. A. Precipitation of sugammadex by protamine. J. Clin. Anesth., 2011, 23, 7, p. 593.
32. Cvachovec, K. Nová farmaka – jak s nimi? Anest. intenziv. Med., 2011, 22, 4, s. 197–199.
33. Kopman, A. F. Neostigmine versus sugammadex: which, when, and how much? Anesthesiology, 2010, 113, 5, p. 1010–1011.
34. Chambers, D., Paulden, M., Paton, F., Heirs, M., Duffy, S., Craig, D., Hunter, J., Wilson, J., Sculpher, M., Woolacott, N. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. Health Technol. Assess., 2010, 14, 39, p. 1–211.
35. Paton, F., Paulden, M., Chambers, D., Heirs, M., Duffy, S., Hunter, J. M., Sculpher, M., Woolacott, N. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. Brit. J. Anaesth., 2010, 105, 5, p. 558–567.
36. Fuchs-Buder, T., Meistelman, C., Schreiber, J. U. Is sugammadex economically viable for routine use. Curr. Opin. Anaesthesiol., 2012, 25, 2, p. 217–220.
Labels
Anaesthesiology, Resuscitation and Inten Intensive Care MedicineArticle was published in
Anaesthesiology and Intensive Care Medicine
2012 Issue 5
Most read in this issue
- Perforated peptic ulcer – pre-operative risks, postoperative morbidity and mortality, prophylaxis in intensive care and guidelines
- Pre-operative assessment
- Sugammadex from the perspective of evidence-based medicine
- What is calcyphylaxis and why we should not supplement calcium in patiens with hyperphosphatemia and phosphates in pateints with hypercalcemia?